Clinical Trial Update: A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study [Phase 4]

View source ↗

Summary

Phase IV, open-label pilot trial assessing potential neurotoxicity of Dolutegravir/Lamivudine/Abacavir and reversibility after switching to Elvitegravir/Cobicis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Dolutegravir/Lamivudine/Abacavir
• Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide

Snippet

Sponsor: Fundacion SEIMC-GESIDA | Conditions: HIV Infections | Phase 4 | Status: COMPLETED